---
title: "Weekly Recap | Vertex Pharma +0.82%, closing in on record highs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298103809.md"
description: "Vertex Pharma (VRTX.US) gained 0.82% this week to close at $546.12, outperforming the S&P 500 by roughly 0.73 percentage points. The share price fell early in the week, bottoming at $532.228 on Monday, then rebounded. Wednesday brought a surge to $556.750 and an intraday record high, and Thursday hit the weekly peak of $560.25 before Friday pared gains to end at $546.12. The weekly range was 5.23%, and average daily volume came in about 18."
datetime: "2026-09-05T08:25:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298103809.md)
  - [en](https://longbridge.com/en/news/298103809.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298103809.md)
generator: "portal-rs"
---

# Weekly Recap | Vertex Pharma +0.82%, closing in on record highs

## The Week

Vertex Pharma (VRTX.US) gained 0.82% this week to close at $546.12, outperforming the S&P 500 by roughly 0.73 percentage points. The share price fell early in the week, bottoming at $532.228 on Monday, then rebounded. Wednesday brought a surge to $556.750 and an intraday record high, and Thursday hit the weekly peak of $560.25 before Friday pared gains to end at $546.12. The weekly range was 5.23%, and average daily volume came in about 18.7% below the median, in a pullback-led, low-volume pattern.

## Key Events

The company-specific story this week centred on two items. On 1 September, Vertex named Jonathan Poole as chief financial officer, effective 1 January 2027. During the same week, Casgevy received an FDA label expansion, prompting discussion on whether VRTX was undervalued. Vertex and Illumina both raised 2026 full-year guidance, and Vertex hit a record high on 2 September, the same day Goldman added the stock to its conviction list. Several broader biotech items on 52-week highs and sector performance also circulated through the week.

## Analyst Ratings

Across 30 firms covering the stock, 19 rate it buy, 5 rate it overweight, 4 hold, 1 underweight and 1 sell, which works out to 24 buy or overweight ratings and 2 underweight or sell ratings. The consensus recommendation is buy, with a consensus target of $569.54, about 4.29% above the latest price. Targets range from $350 to $672, a wide spread. Vertex ranks 4th by analyst rating within its biotech industry, placing it near the front of 507 peers.

## The Week Ahead

There are no Vertex-specific earnings or major events over the coming week; the next scheduled release is the Q3 FY2026 result on 2 November. On the macro side, jobless claims, PPI and existing home sales data due 10 September provide the backdrop for biotech risk appetite. The market reaction to this week’s Casgevy label expansion and the follow-through from Goldman’s conviction-list addition will also be worth monitoring.

## In Short

This week paired a constructive rating backdrop and positive news flow with limited price momentum. Analysts hold a buy consensus, the target sits about 4.29% above spot, and the stock ranks well within its industry. The week also brought a CFO appointment, the Casgevy label expansion and a guidance raise, with an intraday record high. Yet Friday gave back part of the gains and volume stayed below the median throughout, showing no strong influx behind the upside. The next test is whether the Casgevy expansion translates into a more sustained valuation driver and how the stock absorbs the post-spike pullback.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead](https://longbridge.com/en/news/298914581.md)
- [Vertex (VRTX) Stock Still Looks Like A Bargain On Its 181% Run](https://longbridge.com/en/news/298484320.md)
- [VRTX: Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead](https://longbridge.com/en/news/298920359.md)
- [Olympic skier Vonn joins up with Vertex for pain campaign](https://longbridge.com/en/news/299058605.md)
- [Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis](https://longbridge.com/en/news/298806080.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**